CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals’ Australian Subsidiary
·CEPI to provide initial US$3.5m to Clover Biopharmaceuticals Australia, the wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc (China) to support preparation and initiation of a phase 1 trial of Clover’s protein-based COVID-19 S-Trimer vaccine in Australia.
·Partnership becomes ninth global COVID-19 vaccine development project that CEPI has signed since Jan 23, 2020.
OSLO, NORWAY, April 27, 2020
– CEPI, the Coalition for Epidemic Preparedness Innovations, today announced a ninth worldwide collaboration to develop a COVID-19 vaccine. CEPI will invest an initial US$3.5 million in a partnering agreement with Clover Biopharmaceuticals AUS Pty Ltd (“Clover Australia”) a wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc (China) (“Clover Biopharmaceuticals”), bringing the organisation’s total investment in COVID-19 vaccine research & development to US$39.6m.
This initial CEPI investment will support Clover Australia in its efforts to initiate a phase 1 clinical trial in Australia of its COVID-19 S-Trimer vaccine candidate. This innovative vaccine candidate is based on Clover Biopharmaceutical’s proprietary Trimer-Tag©
vaccine technology platform, which is a novel way to produce the spike proteins of the COVID-19 virus in a native trimeric form for use in a vaccine. If successful in clinical trials, Clover Biopharmaceuticals has the capacity to rapidly scale up the production of the vaccine using its in-house biomanufacturing capabilities.
Richard Hatchett, CEO of CEPI said:
“We are delighted to partner with Clover Australia on their innovative COVID-19 S-Trimer vaccine candidate. They produced their vaccine within a month of the virus sequence becoming available, and they have rapidly advanced toward a first in human trial.
“This vaccine candidate is an important new addition to the CEPI portfolio. CEPI has invested in a diverse range of innovative vaccine platforms, as well as more established vaccine technologies, to maximise our chances of success as we pursue our ambition of making COVID-19 vaccines available for broad use.”
Joshua Liang, Chief Strategy Officer of Clover Biopharmaceuticals and co-inventor of COVID-19 S-Trimer vaccine candidate said:
“At Clover Biopharmaceuticals, we are proud to receive CEPI’s funding and support for Clover Australia, which are critical to enabling the ongoing development and acceleration of our COVID-19 S-Trimer vaccine program that utilizes our innovative Trimer-Tag© platform technology. We have been working tirelessly and hope to contribute significantly to global efforts in fighting this pandemic that has affected us all.”
To date, CEPI has provided initial support and funding to Curevac, Inc., Inovio Pharmaceuticals, Inc., Moderna, Inc., Novavax, Inc., The University of Hong Kong, The University of Oxford, The University of Queensland and a consortium led by Institut Pasteur to develop COVID-19 vaccine candidates
This investment is the result of a recent global call for proposals that CEPI issued in early February,
which invited funding applications for vaccine technology that could be used to rapidly develop a vaccine against the new coronavirus, and most importantly at scale and with the necessary equitable access provisions.
CEPI recently officially announced that it has opened a Representative Office in Shanghai. Through its Shanghai Representative Office，CEPI will seek cooperation with China in the prevention and control of pandemic diseases, including funding of public health research projects, technical research and development of vaccines, and international scientific, technology and development cooperation and exchanges.
COVID-19 S-Trimer vaccine
Utilizing Clover’s proprietary Trimer-Tag©
technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development. S-Trimer resembles the native trimeric viral spike protein and is produced via a rapid mammalian cell-culture based expression system.
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at the World Economic Forum at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has reached over US$750 million of its $1 billion funding target. CEPI’s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (ie, Disease X).
Learn more at http://www.cepi.net
. Follow us at @CEPIvaccines
CEPI’s work on COVID-19
The COVID-19 pandemic is a global emergency. CEPI has moved with great urgency and in coordination with WHO, who is leading the development of a coordinated international response. So far, we have initiated nine partnerships to improve our understanding and to develop vaccines against the novel coronavirus. The programmes will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.
Follow our news page
for the latest updates.
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. Having raised more than US$ 100 million in total capital since 2016, Clover is utilizing its proprietary Trimer-Tag©
technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house GMP biomanufacturing capabilities to support large-scale production of its biologic therapies. For more information, please visit our website: www.cloverbiopharma.com.
Phone: +44 7387 055214
+86 028 63925786